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Background: Chronic inflammatory demyelinating polyneuropathy (CIDP) as a pure sensory variant is rarely
encountered. Therefore the best treatment option is hard to define.
Case presentations: We reported two middle-aged patients of Caucasian origin, one female and one male, who
over a period of several months presented limbs and gait ataxia. Clinical and neurophysiological examination
revealed only sensory abnormalities. A diagnosis of atypical CIDP was suggested, considering the elevated CSF
protein level and the presence of anti-gangliosides antibodies. Ten and 15 days respectively after initiation of
prednisolone treatment both patients experienced exacerbation of sensory symptoms and emerging of muscle
weakness. Steroids were then substituted by rituximab in the first patient and intravenous immunoglobulin in the
second patient resulting in gradual decrement of symptoms and signs. Two-year follow-up showed no further
deterioration.
Conclusion: Caution should be exercised when treating cases of pure sensory polyneuropathy with high dose
steroids since an unfavorable outcome is possible.
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treatmentBackground
Pure sensory neuropathy is an uncommon condition
which in most cases is considered idiopathic and catego-
rized under the range of chronic axonal neuropathy or
cryptogenic polyneuropathy [1,2]. Fewer cases of sensory
polyneuropathy have been identified as an entity within
the spectrum of chronic inflammatory demyelinating
polyneuropathy (CIDP) [3,4]. The latter cases have at
least subclinical involvement of motor components and
thus fulfill the diagnostic criteria for CIDP [5,6]. In a re-
cent study, 22 patients with responding to immunother-
apy sensory polyneuropathy but without clinical or
electrophysiological criteria for motor involvement were
considered to have a pure sensory variant of CIDP [7].* Correspondence: echroni@yahoo.com
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unless otherwise stated.The recognition of an auto-immune nature of the sen-
sory neuropathy justifies treatment attempts with 1st
line medication for CIDP. However, due to the relatively
small number of cases reported in the literature the re-
sponse to treatment is not well known. It is possible that
as in other atypical forms of CIDP one drug may be
preferable to another. We herein report on two patients
with pure sensory polyneuropathy who experienced
rapid deterioration following steroid administration.Case presentation
History and clinical presentation
First patient
A 58 year old Caucasian female presented with a 12 month
history of progressively worsening numbness in her hands
and feet and impaired balance which caused infrequent
falls. She was previously healthy, denied alcohol or chem-
ical agents’ consumption and had a family history of bowelThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Electrophysiological results in two patients with
clinically pure sensory deficits
Motor conduction
Ulnar nerve Fibular nerve
Pt. 1 Pt. 2 Normal
limit




2.8 3.1 <3.5 3.7 4.8 <5.0
Amplitude
(mV)#
8.3/8.0 6.8/6.4 >5.0 3.9/3.2 3.4/3.1 >2.0
Duration
(ms)#
4.6/5.3 5.1/5.7 <6.7§ 4.8/5.4 6.3/6.5 <7.6§
Velocity (m/s) 60 50 ≥50 46 39 ≥41
F wave lat.
min/max (ms)
31/35 32/37 <32/35* 50/61 55/69 <55/64*
F wave
persistence (%)
90 80 >70 70 50 >20
Sensory conduction
Median nerve Ulnar nerve
Pt. 1 Pt. 2 Normal
limit
Pt. 1 Pt. 2 Normal
limit
Amplitude (μV) 2.0 Absent >10 1.7 Absent >7
Velocity (m/s) 48 - ≥50 56 - ≥45
Radial nerve Sural nerve
Pat1 Pat2 Normal
limit
Pat 1 Pat 2 Normal
limit
Amplitude (μV) 5.9 4.5 >15 14 3.4 >7
Velocity (m/s) 63 58 ≥55 62 43 ≥45
#Measurements following stimulation at the wrist/above elbow and at the
ankle/above knee.
*Calculated from samples of 20 F waves for the patients’ age and height;
§duration limits were adopted from those published by EFNS/PNS [11].
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pin-prick and touch sensation in a stocking-glove distribu-
tion, severely reduced vibration sense to the knee level
and impaired joint position sense at the great toe bilat-
erally. She had absent all deep tendon reflexes, but normal
muscle strength throughout, intact cranial nerves and
flexor plantar responses. The patient’s stance and gait was
wide-based, tandem gait was impaired, Romberg’s sign
positive and her score on the Overall Neuropathy Limita-
tions Scale (ONLS) [8] was 3 (1 on the arm scale).
Second patient
A ship captain, 55 year old Caucasian male, presented
with an 18 month history of symmetrical and progres-
sive numbness and paresthesia in his feet, which over
the last 6 months spread proximally and affected his
hands as well. He had a personal and family history of
coronary heart disease. He did not smoke, drink alcohol,
use drugs or dietary supplements. On neurological
examination there was reduced touch and pricking pain
sensation distally up to the wrist and ankle level, sup-
pressed vibration sense at the great toe bilaterally and
generalized areflexia. Cranial nerves and muscle strength
examination showed no deficits. Walk was unsteady,
tandem gait was performed with difficulty, Romberg’s
sign positive and his ONLS score was 1 (on the leg
scale).
Sensory assessment testing
To depicture the extension and severity of the sensory
deficit we chose to present the findings by means of an ex-
tended version of Neuropathy Impairment Score–more
specifically the sensation part- (NISsen) [9,10] in order to
assess four sensory modalities: touch-pressure, pricking
pain, vibration and joint position at the index finger, wrist,
elbow, great toe, ankle and knee level bilaterally. Normal
was marked as 0 score, decreased function as 1 and absent
function as 2 score. In particular for vibration sense a
Rydel-Seiffer graduated tuning fork was used with a scale
imprinted on the weights from 0 minimum to 8 max-
imum. Quantitative vibration estimations up to 5 on the
tuning fork scale were considered mildly decreased sense
and were graded as 1, whereas estimations lower than 5
on the 0–8 scale were graded as 2. According to the above
scoring system, the lowest limit on the total of all scales
was 96. At presentation the first patient had a total score
of 30 and the second patient 18.
Neurophysiological examination
The patients underwent the following electrophysio-
logical tests: a. motor conduction and F waves study of
the ulnar, median, fibular and tibial nerves bilaterally
using bipolar surface recording and stimulation elec-
trodes; the compound muscle action potential (CMAP)was obtained from the abductor digiti minimi (ADM),
abductor pollicis brevis (APB), extensor digitorum brevis
(EDB) and abductor hallucis muscle respectively; b. mag-
netic stimulation at Erb’s point and C7 cervical root in
order to elicit CMAP from ADM, APB and at the poplit-
eal fossa and L5 lumbar root level to elicit CMAP from
EDB muscle bilaterally; c. sensory conduction of the
ulnar and median nerves (orthodromic technique, digital
ring stimulating electrodes) and the radial and sural
nerves bilaterally (antidromic technique, bipolar surface
stimulating and recording electrodes); d. needle electro-
myographic sampling of biceps brachii, 1st dorsal inter-
osseous, vastus lateralis and tibialis anterior muscles
unilaterally; e. somatosensory evoked potentials (SSEPs)
in the first patient only. Representative neurophysio-
logical measurements are showed in Table 1. All param-
eters of motor nerve conduction were within normal
limits except for the F wave maximum latency which
was slightly prolonged in the second patient. Proximal
conduction abnormalities i.e. motor conduction block,
defined as >50% CMAP amplitude and area drop in
Figure 1 Clinical assessment scores of a 58 year old woman are
plotted against treatment regime at different time-points.
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persion, defined as proximal duration increased > 30%,
were not detected by magnetic stimulation. Sensory nerve
action potentials (SNAPs) had reduced amplitude or were
absent in the upper limbs, the sural nerve potentials were
comparatively less affected and the sensory velocity nor-
mal (Table 1) There were no signs of denervation in nei-
ther of the patients. Briefly, the findings, which were
similar in both patients, were compatible with sensory
component disturbance that can be attributed to sensory
neuropathy or neuronopathy. SSEPs to median nerve
stimulation showed ill-formed responses with prolonged
latency and low amplitude at the cortical level (N20 right/
left: 26.5 ms/24.3 ms) and non-reproducible potentials at
Erb’s point bilaterally; tibial nerve stimulation showed ab-
sent lumbar and cortical responses bilaterally.
Laboratory evaluation
In both cases, the following blood tests were normal or
negative: complete blood count, erythrocyte sedimenta-
tion rate, blood glucose, electrolytes, renal and liver
function tests, thyroid function tests, serum protein elec-
trophoresis and serum immunofixation, serum vitamin
B12, vitamin E (70 and 76 μg/ml in the 1st and 2nd pa-
tient respectively), C-reactive protein, antinuclear anti-
bodies, anti-SSA & anti-SSB, c-ANCA & p-ANCA, RPR,
HIV, HTLV and paraneoplastic antibody screening,
which included antibodies against Hu, Yo (1st patient
only), amphiphysin, SOX1 and CV2/CRMP5. Testing for
anti-ganglioside antibodies was negative for anti-MAG
(IgM class), GM1, GM2, GQ1b, GD1b, GD3 and sulfa-
tide in both subjects, strongly-positive but without spe-
cific isotype detection for anti-GD1a and GT1b in the
first patient and for anti-GT1a in the second patient.
Cerebrospinal fluid (CSF) examination showed a protein
level of 0.65 g/L (normal <0.45 g/L) with 3 white blood
cells in the first case and 1.53 g/L with 11 white blood
cells in the second case supporting an albuminocytolo-
gic dissociation. In both patients Schirmer-I test and
Rose-Bengal score were negative; chest and abdomen
computed tomography scans, mammography (1st pa-
tient) and colonoscopy showed no signs of malignancy,
whereas magnetic resonance imaging scans of the brain,
cervical and lumbar spine were negative.
Treatment and follow-up
The first patient was initially treated with prednisolone
(60 mg p.o. daily) but within 10 days she reported increase
of unsteadiness and numbness which also involved the tri-
geminal nerve region. Nevertheless, according to the in-
structions she completed a two-month period of steroid
treatment. At that time her sensory deficits enhanced, she
manifested weakness of quadriceps and wrist extensor
muscles (expanded MRC score reduced from 70 to 66)and became unable to walk without bilateral support. She
scored 6 on the ONLS (2 on the arm scale). Prednisolone
was tapered off and intravenous immunoglobulin (IVIg)
therapy was started at a dose of 0.4 mg/kg/day. The sec-
ond day of infusion the patient manifested severe head-
ache, nausea, fever, nuchal rigidity and confusion. A
second CSF analysis showed neutrophilic pleocytosis (700
white blood cells/mL, normal glucose and 0.93 g/L pro-
tein). Following thorough laboratory investigation a diag-
nosis of aseptic meningitis was made and IVIg treatment
was discontinued. A course of rituximab (i.v. infusions at a
dosage of 375 mg/m2 weekly for 4 weeks) was tried as a
second-line treatment according to recent literature [12].
Three months following steroid withdrawal the patient’s
clinical status returned to pre-steroid level (Figure 1). Two
years later, following another two rituximab infusions, the
patient was able to walk unaided and reported only min-
imal distal numbness of her hands and feet.
The second patient was started on oral prednisolone
(60 mg daily) but from day 15 he experienced exacerba-
tion of ataxia and spreading of the numbness. Steroid ta-
pering was scheduled 20 days from treatment onset
since the patient developed diplopia, numbness in the
face, inability to perform fine hand’s movements, stand
or walk 1 meter (expanded MRC score 64; ONLS arm
grade 4, leg grade score 5). Within the next month the
patient’s condition improved significantly; his cranial
nerve deficits and muscle weakness disappeared and he
was able to walk again with support for a few meters.
Monthly infusions of IVIg at an initial dose of 0.4 g/kg
daily for 5 days and maintenance dose of 0.5 g/kg for
2 days) had a beneficial but short-lived effect on this pa-
tient, requiring monthly treatment repetitions (Figure 2).
Figure 2 Clinical assessment scores of a 55 year old man are
plotted against treatment regime at different time-points.
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ther improved by IVIg infusions every 4–6 months and
he was able to return to his work.
Discussion
The disease characteristics, shared by the two patients
were: i. pure sensory deficits; ii. a chronic, slowly pro-
gressive course, over the duration of several months; iii.
sensory ataxia that predominated clinically, affecting
both the upper and lower limbs; iv. early areflexia
throughout; v. raised protein levels without cells in the
CSF; vi. low amplitude of (SNAPs), especially the “abnor-
mal ulnar-radial/normal sural” pattern, along with the
absence of any motor nerve conduction abnormalities.
Two additional characteristics were added shortly (10–
15 days) after administration of prednisolone: vii. cranial
nerve involvement and viii. muscle weakness. Sensory
ataxia could theoretically be due to dorsal root ganglio-
nopathy [4,13]. According to the American-European
Consensus Group, a diagnosis of Sjögren’s syndrome
was not established in our patients, since neither of
them fulfilled the requirement for the presence of 4 out
of 6 criteria [14]. More specifically, both patients had no
ocular or oral symptoms, ocular signs and anti-SSA &
anti-SSB antibodies. A paraneoplastic syndrome, which
cannot be entirely ruled out, is highly unlikely given the
above disease’s characteristics iv-vii. A diagnosis of
chronic axonal polyneuropathy was also considered.
However, the predominance of ataxia and areflexia in
the absence of neuropathic pain, the presence of anti-
gangliosides antibodies and the increased CSF protein
level implying an intrathecal process, made the diagnosis
of sensory polyradiculo-neuropathy more suitable [1].According to the current criteria set by the European
Federation of Neurological Societies/Peripheral Nerve
Society our cases should be considered as atypical CIDP
[11]. Indeed, the authors of a retrospective study de-
scribed patients with the above clinical features of a
chronic sensory polyneuropathy and concluded that they
all had sensory CIDP [7]. We acknowledged the omis-
sion of spinal roots/ plexus MRI and nerve biopsy in our
patients, which may not be necessary examinations for
the diagnosis, but they would have further supported
our view.
Immune-mediated sensory polyradiculo-neuropathies
have long been recognized as a specific type of CIDP. The
majority of patients with only sensory symptoms are likely
to develop subclinical motor conduction abnormalities
and thus become compatible with CIDP [3,5]. However,
some patients have normal nerve conduction measure-
ments but abnormal somatosensory evoked potentials [4]
and others, as our patients, have sensory conduction ab-
normalities indicative of chronic axonal polyneuropathy
[15,16], thus failing to meet the electrodiagnostic criteria
for definite CIDP [11]. Nevertheless, it was decided the
patients receive treatment since their neurological condi-
tion had a prolonged negative impact upon daily living
activities. According to guidelines for CIDP sufferers,
including patients with pure sensory manifestations
[5,7,11,17,18] and availability of medication at the time
prednisolone was our first choice.
Initiation of steroids was followed by severe worsening
of disability which in both cases was completely reversible
after steroid substitution with alternative medication. The
possibility of incidental deterioration, irrespective of treat-
ment, was unlikely since prior to the administration of ste-
roids both patients had a slowly progressive course over
several months which allowed them to be independent
and continue to work, while within a few days of treat-
ment onset ataxia increased to the extent that they were
unable to walk unaided, developing motor impairment for
the first time. The re-initiation of steroids in our patients
could possibly have supported our hypothesis on their
negative effect, yet it was not attempted for ethical rea-
sons, whilst both patients did not wish for us to do so. A
single case of pure sensory CIDP where severe deterior-
ation was noted within days of steroid administration has
recently been reported in the literature [19]. In a series of
13 patients with chronic sensory ataxia and positive anti-
GD1b antibodies IVIg administration was successful in 9
patients, whereas steroid treatment resulted in a mod-
erate improvement in only 1 out of 4 patients [20]. It
could be assumed that steroids alter the balance of
lymphocyte subpopulation in favor of B cells, thus in-
creasing the circulating autoantibodies [21]. An unex-
pected motor deterioration after plasma exchange has
been reported in two patients with sensory CIDP and
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genic and protective autoantibodies [22]. Clinical trials
have demonstrated worsening in typical and atypical
CIDP cases under steroid treatment [23,24]. Specifically
for pure motor CIDP recommendations against the use
of steroids have been given [11,25]. In analogy, the un-
favorable response to steroid treatment in the present
study implies that prednisolone may be harmful in
some cases of sensory CIDP.
Conclusion
We suggested that caution should be exercised when
treating cases of pure sensory polyneuropathy with high
dose steroids since an unfavorable outcome is possible.
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